CLINICAL_TRIALS
ClinicalTrials.gov record update
Safety and Efficacy of SRS and Immune Checkpoint Inhibitors (ICI) Concurrent With NovoTTF-200M in Melanoma Brain Metastases
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT05341349
- Title field or adapter rule
- protocolSection.identificationModule.officialTitle
- Ingested At
- 2026-04-25T22:29:03.758888+00:00
- Published At
- 2026-04-23T00:00:00+00:00
- Record Updated At
- 2026-04-23
- Timestamp Basis
- source retrieval time was not retained by the feed adapter
- Date limitation
- source retrieval time was not retained by the feed adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["Clinical Stage IV Cutaneous Melanoma AJCC v8", "Melanoma of Unknown Primary", "Metastatic Malignant Neoplasm in the Brain", "Metastatic Melanoma", "Metastatic Mucosal Melanoma", "Metastatic Ocular Melanoma", "Pathologic Stage IV Cutaneous Melanoma AJCC v8"]- protocolSection.statusModule.lastUpdatePostDateStruct.date
"2026-04-23"- protocolSection.identificationModule.nctId
"NCT05341349"- protocolSection.identificationModule.officialTitle
"Safety and Efficacy of SRS and Immune Checkpoint Inhibitors (ICI) Concurrent With NovoTTF-200M in Melanoma Brain Metastases"- protocolSection.statusModule.overallStatus
"TERMINATED"- protocolSection.designModule.phases
["PHASE1"]- protocolSection.statusModule.resultsFirstPostDateStruct.date
""
Study condition terms
Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.